Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study
Effekt einer Behandlung mit mucoaktiven Arzneimitteln auf COPD-Exazerbationen während 5 Jahren Nachbeobachtung in der Tschechischen Republik: Real-World-Studie
Lung · 2025-12 · 203 (1)
DOI: 10.1007/s00408-025-00813-7 ↗Auf einen Blick
Bei 452 Erwachsenen mit COPD war eine 24-monatige mucoaktive Behandlung mit einer stärkeren Reduktion von Exazerbationen über 5 Jahre verbunden als keine mucoaktive Behandlung.
Fragestellung
Welchen Effekt hat eine langfristige mucoaktive Behandlung auf Exazerbationen bei COPD in der Tschechischen Republik?
Methode
Prospektive, multizentrische, beobachtende Real-World-Studie mit 452 Erwachsenen aus der Czech Multicenter Research Database of COPD; Follow-up 5 Jahre.
Ergebnisse
81 Patient:innen erhielten 24 Monate mucoaktive Arzneimittel, 371 keine. Die Reduktion aller Exazerbationen war in Jahr 1 bis 5 größer als in der Kontrollgruppe (−0,61 vs. −0,18; −0,54 vs. −0,09; −0,55 vs. 0,04; −0,67 vs. 0,13; −0,53 vs. 0,10; p=0,026/0,007/0,005/0,002/0,019).
Schlussfolgerung der Autor:innen
Eine 2-jährige mucoaktive Behandlung verringerte über 5 Jahre die Zahl aller und moderaten COPD-Exazerbationen; der Effekt war bei Husten oder COPD-Stadium 3–4 stärker und unabhängig von ICS.
Kernaussagen
- 24 Monate mucoaktive Behandlung waren mit weniger COPD-Exazerbationen verbunden.
- Der Effekt zeigte sich über 5 Jahre für alle und moderate Exazerbationen.
- Stärkerer Rückgang bei Husten oder COPD-Stadium 3–4; unabhängig von ICS.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Beobachtungsstudie in der Zeitschrift Lung, online erschienen am 06.05.2025. Verfasst von Jaromír Zatloukal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Expectorants, Acetylcysteine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky, Cooperatio Charles University, Czechia, Charles University.
Themen: COPD
Abstract (Originalsprache)
Introduction
Studies indicate that chronic treatment with mucoactive drugs may reduce COPD exacerbation rates. This real-world, multicenter, prospective, observational study aimed to determine the effect of long-term mucoactive treatment on exacerbations in patients with COPD in the Czech Republic.
Methods
452 adult patients on the Czech Multicenter Research Database of COPD with post-bronchodilator FEV 1 ≤ 60% of predicted value received standard of care and were followed up for 5 years. For the first 24 months, 81 patients received regular thiol-based mucoactive drugs (77 erdosteine, 4 N-acetylcysteine) at the discretion of the treating physician and 371 patients had no mucoactive treatment (control group). Erdosteine was fully reimbursed, and NAC was partially reimbursed for COPD patients. The annual number/rate of COPD exacerbations over 5 years was monitored.
Results
Patients receiving mucoactive treatment for 24 months had a significantly larger reduction from baseline in all exacerbations compared to the control group (− 0.61 vs − 0.18, p = 0.026; − 0.54 vs − 0.09, p = 0.007; − 0.55 vs 0.04, p = 0.005; − 0.67 vs 0.13, p = 0.002; − 0.53 vs 0.10, p = 0.019 in the first to fifth year, respectively). The reduction in moderate exacerbations was also significantly larger in those receiving mucoactive treatment versus no mucoactive treatment. The exacerbation rate was reduced to a greater extent in the subgroups with cough or with stage 3‒4 COPD who received mucoactive treatment but was independent of the use of inhaled corticosteroids (ICS).
Conclusion
Mucoactive treatment for two years reduced the number of COPD exacerbations (all, moderate) over five years of follow-up. The reduction in exacerbations was more pronounced in patients with cough or with stage 3‒4 COPD but was independent of the use of ICS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic.
- Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- Institute of Pharmaceutical Science, King's College London, London, UK.
- Department of Pulmonary Diseases and Tuberculosis, Masaryk University, Brno, Czech Republic.
- Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- Institute of Biostatistics and Analyses Ltd, Brno, Czech Republic.
Förderung
- Ministerstvo Zdravotnictví Ceské Republiky
- Cooperatio Charles University, Czechia
- Charles University
Zitieren
APA
Zatloukal, J., Page, C., Brat, K., Svoboda, M., Voláková, E., Plutinský, M., Kopecký, M., & Koblížek, V. (2025). Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study. Lung, 203(1). https://doi.org/10.1007/s00408-025-00813-7
Vancouver
Zatloukal J, Page C, Brat K, Svoboda M, Voláková E, Plutinský M, et al. Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study. Lung. 2025;203(1). doi:10.1007/s00408-025-00813-7
BibTeX
@article{Zatloukal2025,
author = {Zatloukal, Jaromír and Page, Clive and Brat, Kristián and Svoboda, Michal and Voláková, Eva and Plutinský, Marek and Kopecký, Michal and Koblížek, Vladimír},
title = {Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study},
journal = {Lung},
year = {2025},
volume = {203},
number = {1},
doi = {10.1007/s00408-025-00813-7}
}
EUVIMED